Baseline characteristics
| Characteristic . | Ivosidenib 500 mg + chemotherapy, n = 60 . | Enasidenib 100 mg + chemotherapy, n = 93 . |
|---|---|---|
| Age, median (range), y | 62.5 (24-76) | 63.0 (27-77) |
| Age category, n (%), y | ||
| <60 | 21 (35) | 34 (37) |
| ≥60 | 39 (65) | 59 (63) |
| Men, n (%) | 30 (50) | 52 (56) |
| Type of AML, n (%) | ||
| De novo | 42 (70) | 58 (62) |
| Secondary | 18 (30) | 35 (38) |
| Prior hypomethylating agent, n (%)* | 4 (22) | 17 (49) |
| IDH1 mutation type, n (%)† | ||
| R132 | 58 (97) | 2 (2) |
| Other or unknown | 2 (3) | 1 (1) |
| IDH2 mutation type, n (%)† | ||
| R140 | 1 (2) | 66 (71) |
| R172 | 1 (2) | 25 (27) |
| Other or unknown | 0 | 2 (2) |
| Cytogenetic risk status by investigator, n (%) | ||
| Favorable | 0 | 2 (2) |
| Intermediate | 42 (70) | 64 (69) |
| Poor | 13 (22) | 20 (22) |
| Unknown | 5 (8) | 7 (8) |
| Characteristic . | Ivosidenib 500 mg + chemotherapy, n = 60 . | Enasidenib 100 mg + chemotherapy, n = 93 . |
|---|---|---|
| Age, median (range), y | 62.5 (24-76) | 63.0 (27-77) |
| Age category, n (%), y | ||
| <60 | 21 (35) | 34 (37) |
| ≥60 | 39 (65) | 59 (63) |
| Men, n (%) | 30 (50) | 52 (56) |
| Type of AML, n (%) | ||
| De novo | 42 (70) | 58 (62) |
| Secondary | 18 (30) | 35 (38) |
| Prior hypomethylating agent, n (%)* | 4 (22) | 17 (49) |
| IDH1 mutation type, n (%)† | ||
| R132 | 58 (97) | 2 (2) |
| Other or unknown | 2 (3) | 1 (1) |
| IDH2 mutation type, n (%)† | ||
| R140 | 1 (2) | 66 (71) |
| R172 | 1 (2) | 25 (27) |
| Other or unknown | 0 | 2 (2) |
| Cytogenetic risk status by investigator, n (%) | ||
| Favorable | 0 | 2 (2) |
| Intermediate | 42 (70) | 64 (69) |
| Poor | 13 (22) | 20 (22) |
| Unknown | 5 (8) | 7 (8) |